Clinical Trial Update: Oritavancin for Staphylococcus Aureus Infections in Opioid Users [Phase 4]

View source ↗

Summary

Phase 4 trial of oritavancin for Staphylococcus aureus infections in opioid users has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia
• Staphylococcus Aureus Endocarditis

Drugs mentioned

• Oritavancin (oritavancin)

Snippet

Sponsor: University of Pennsylvania | Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 4 | Status: WITHDRAWN